Daniel E Pleguezuelo Raquel Díaz-Simón Oscar Cabrera-Marante Antonio Lalueza Estela Paz-Artal Carlos Lumbreras Antonio Serrano Hernández
10.3389/fimmu.2021.667515
Front Immunol
2021 Apr 12;12:667515.
anti-cd38 anti-phospholipid daratumumab refractory treatment
CC BY
https://pubmed.ncbi.nlm.nih.gov/33912194/
Antibodies, Antiphospholipid / blood Antibodies, Monoclonal / therapeutic use Antiphospholipid Syndrome / drug therapy Immunity, Humoral / drug effects Immunologic Factors / therapeutic use Plasma Cells / drug effects Venous Thromboembolism / prevention & control
Antibodies, Antiphospholipid / blood Antibodies, Monoclonal / therapeutic use Antiphospholipid Syndrome / drug therapy Immunity, Humoral / drug effects Immunologic Factors / therapeutic use Plasma Cells / drug effects Venous Thromboembolism / prevention & control Case Reports Research Support, Non-U.S. Gov't Anticoagulants / therapeutic use Antiphospholipid Syndrome / blood Antiphospholipid Syndrome / diagnosis Antiphospholipid Syndrome / immunology Biomarkers / blood Female Humans Off-Label Use Plasma Cells / immunology Plasma Cells / metabolism Recurrence Treatment Outcome Venous Thromboembolism / blood Venous Thromboembolism / diagnosis Venous Thromboembolism / immunology Young Adult Antibodies, Antiphospholipid Antibodies, Monoclonal Anticoagulants Biomarkers Immunologic Factors daratumumab
PMC8072150
33912194
Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome
2021